Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 4/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | USP8 | P40818 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5644362 | 0.79 | TP53 (0.35) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL620504 | 0.77 | USP8 (0.42) | USP8KDM4E | |
| SCHEMBL1396863 | 0.75 | CHEK1 (0.57) | CDK1CHEK1CHEK2KCNH2 | |
| SCHEMBL1397487 | 0.75 | CHEK1 (0.57) | CDK1CHEK1CHEK2KCNH2 | |
| SCHEMBL12984885 | 0.75 | CHEK1 (0.57) | CDK1CHEK1CHEK2KCNH2 | |
| SCHEMBL5642222 | 0.74 | CDK1 (0.38) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL1397037 | 0.74 | CHEK1 (0.45) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL19361937 | 0.72 | CHEK1 (0.43) | CDK1CHEK1CHEK2KCNH2 | |
| SCHEMBL15142766 | 0.71 | PIK3CD (0.40) | USP8HTTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL1396879 | 0.71 | KDM4E (0.51) | KDM4EALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288601-B1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | CDK1 6/4885CCNB1 15/4885CCNA2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.